GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Intrinsic Value: Projected FCF

Alliance Pharma (LSE:APH) Intrinsic Value: Projected FCF : £0.87 (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-29), Alliance Pharma's Intrinsic Value: Projected FCF is £0.87. The stock price of Alliance Pharma is £0.3495. Therefore, Alliance Pharma's Price-to-Intrinsic-Value-Projected-FCF of today is 0.4.

The historical rank and industry rank for Alliance Pharma's Intrinsic Value: Projected FCF or its related term are showing as below:

LSE:APH' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.4   Med: 1.16   Max: 1.93
Current: 0.4

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Alliance Pharma was 1.93. The lowest was 0.40. And the median was 1.16.

LSE:APH's Price-to-Projected-FCF is ranked better than
95.82% of 598 companies
in the Drug Manufacturers industry
Industry Median: 1.53 vs LSE:APH: 0.40

Alliance Pharma Intrinsic Value: Projected FCF Historical Data

The historical data trend for Alliance Pharma's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Intrinsic Value: Projected FCF Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.74 0.86 0.89 0.87

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.89 - 0.87 -

Competitive Comparison of Alliance Pharma's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Price-to-Projected-FCF falls into.



Alliance Pharma Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Alliance Pharma's Free Cash Flow(6 year avg) = £25.88.

Alliance Pharma's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec22)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*25.879285714286+287.661*0.8)/545.281
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma  (LSE:APH) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Alliance Pharma's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.3495/0.87387732023017
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q3 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

The Amphenol Corp (APH) Company: A Short SWOT Analysis

By GuruFocus Research 10-30-2023

Q2 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amphenol Announces Third Quarter 2023 Dividend

By Business Wire 08-04-2023

Q3 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024